Patents by Inventor Saliha Moussaoui

Saliha Moussaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210269881
    Abstract: The present invention describes a method for the therapeutic treatment and/or for the diagnosis of a brain disorder including but not limited to cognitive disorders such as mild cognitive impairment, Alzheimer disease, frontotemporal dementia, dementia with Lowy body in a subject at risk of having or developing a brain disorder such as cognitive disorder, using long non-coding RNA (IncRNA).
    Type: Application
    Filed: September 5, 2019
    Publication date: September 2, 2021
    Inventors: Saliha MOUSSAOUI, Hueseyin FIRAT, Eric SCHORDAN
  • Publication number: 20210071252
    Abstract: The present invention describes a method for the diagnosis of a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder.
    Type: Application
    Filed: September 5, 2018
    Publication date: March 11, 2021
    Inventors: Hueseyin FIRAT, Saliha MOUSSAOUI, Eric SCHORDAN
  • Publication number: 20190094246
    Abstract: The present invention relates to a biomarker, and/or methods including a non-invasive in vitro method using this biomarker, for diagnosing or monitoring the development or the progression of Alzheimer's disease (AD) or a disease or disorder associated with ?-amyloid peptide (A?) deposition or tau hyperphosphorylation or a disease or disorder characterized by a proteinopathy implicating abnormalities in protein kinase C (PKC).
    Type: Application
    Filed: March 7, 2017
    Publication date: March 28, 2019
    Inventors: Saliha MOUSSAOUI, Dirk WILDEMANN, Holger WENSCHUH, Karsten SCHNATBAUM, Gilles ULRICH, Jean DE BARRY, Corinne MBEBI-LIEGEOIS, Hueseyin FIRAT
  • Patent number: 9458112
    Abstract: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 4, 2016
    Assignee: NOVARTIS AG
    Inventors: Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Jones, Paul William Manley, Andreas Marzinzik, Saliha Moussaoui, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Publication number: 20160185733
    Abstract: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Application
    Filed: March 4, 2016
    Publication date: June 30, 2016
    Applicant: NOVARTIS AG
    Inventors: Pascal FURET, Robert Martin GROTZFELD, Wolfgang JAHNKE, Darryl JONES, Paul William Manley, Andreas MARZINZIK, Saliha MOUSSAOUI, Xavier Francois Andre PELLE, Bahaa SALEM, Joseph SCHOEPFER
  • Patent number: 9315489
    Abstract: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 19, 2016
    Assignee: Novartis AG
    Inventors: Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Brynley Jones, Paul William Manley, Andreas Marzinzik, Saliha Moussaoui, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Publication number: 20150141427
    Abstract: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 21, 2015
    Applicant: Novartis AG
    Inventors: Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Brynley Jones, Paul William Manley, Andreas Marzinzik, Saliha Moussaoui, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Publication number: 20100076024
    Abstract: The invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1; to compositions comprising said compounds and to their use as pharmaceutical agents, in particular as inhibitors of serine proteases.
    Type: Application
    Filed: February 20, 2008
    Publication date: March 25, 2010
    Inventors: Kaspar Zimmermann, Daniel Kaspar Baeschlin, Saliha Moussaoui
  • Patent number: 6387936
    Abstract: The invention concerns a combination of levodopa and riluzole or a pharmaceutically acceptable salt of said compound and the use of said combination for treating Parkinson Disease.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: May 14, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: VĂ©ronique Blanchard-Bregeon, Assunta Imperato, Saliha Moussaoui, Marie-Carmen Obinu, Michel Reibaud